Replies to post #699332 on NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

hankman - Try Doc Logic's response to Vator below for information related to your question:

vator,

DCs require proper activation and maturation for any particular desired function. The combinations of this process are virtually limitless which creates safety in specificity. Specificity is created by signaling that often times creates on/off switching to genetic functions and pathways. There are different areas of study in this regard and this current announcement is basically pointing to a method for improved signaling that allows DCs to further educate and or prepare a clearer path for the rest of the immune system. What NWBO has is still primary but like I have said before, there are many ways to increase specificity and increase ability to access and destroy targets that otherwise might remain hidden.
The basic understanding shared on this board about the advantages seen from methylated status with regard to DC treatment vs non methylated status is just one example of the open pathway vs closed pathway that additional specificity with signaling could overcome. This currently would require an outside source of CSF-R1 in addition to DCVax-L and likely anti PD1 as well in some to many cases.
Bottom line is that there is synergy and this union is making it much more difficult for big pharma to get in the way of a pathway to a cure. Best wishes.

[learningcurve2020]

Are you sure? Feels to me like her fallback for when L gets rejected.

>>NWBO already has a platform for all solid cancers.

[georgebailey]

Hankman- the DC platform IP moat-
the Roswell IP and its associated value to nwbo….” I a sure something was there”.
A simple explanation as to why is that, those Roswell patents could represent a work around of DC based treatments and complimentary DC IP such as MSDC ——-LP is building the DC platform IP moat when bringing in Roswell IP.

[newman2021]

The MSDC! It does what CI does right - dealing ith the immunosuppressive layer; but no toxic is the key. And when combined with DcVax, LP is expecting it to do wonders ..... without the need of CIs to cure cancer. All imo.

[Doc logic]

hankmanhub,

What is offered is a counter to checkpoint inhibitor resistance. This of course helps checkpoint inhibitors work better but also DC therapy work better. This is likely the big reason for some of the angst expressed here by those perhaps tied into big pharma by heavy investment or other. This tech would have helped big pharma leverage their products better with regard to positional importance in combos or other with L too.
Bottom line, this agreement means more potential leverage lost by big pharma. They now need NWBO more than ever. Let’s see how long it takes for Mr Market to figure this out. Best wishes.